Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting
| Overview / Abstract: |
In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care. Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide information"on such issues as optimal regimen selection, the role of minimal residual disease (MRD) as a treatment goal, the use of emerging targeted and immunotherapeutic therapies, and management of treatment-related toxicities"that is potentially relevant to optimizing outcomes but that is likely not reflected in current guidelines. These advances pose formidable challenges to community oncology health care providers (HCPs). This activity, developed for hematologist-oncologists, medical oncologists, and other HCPs, has been designed to bridge the gap between prevailing but potentially suboptimal MM treatment practices and novel recommended therapies and to ensure that clinicians are able to apply evidence that can lead to improved patient outcomes in diverse MM patient populations. |
|
Expiration |
Dec 01, 2023 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online |
|
Credits / Hours |
0.75 AMA PRA Category 1 Credit™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Craig Emmitt Cole, MD Laura Finn, MD, MS Joshua Richter, MD |
|
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through educational grants from AbbVie, Bristol Myers Squibb, and Janssen. |
|
Keywords / Search Terms |
B-cell maturation antigen, BCMA, belantamab mafodotin, belmaf, bispecific antibodies, bortezomib, carfilzomib, CAR T-cell therapy, cilta-cel, ciltacabtagene autoleucel, CureCloud, cytokine release syndrome, daratumumab, dexamethasone, elranatamab, idecabtagene vicleucel, immunotherapy, lenalidomide, pomalidomide, relapsed/refractory multiple myeloma, selinexor, talquetamab, teclistamab, tocilizumab, free, cme, redmeded |
|